Evidence map›Paper›PMID 38561682›Full record

Trial reportBMC neurology2024

A randomized feasibility trial of medium chain triglyceride-supplemented ketogenic diet in people with Parkinson's disease.

Alexander H Choi, Melanie Delgado, Kong Y Chen, Stephanie T Chung, Amber Courville, Sara A Turner, Shanna Yang, Kayla Airaghi, Irene Dustin, Patrick McGurrin and 3 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04584346 (Acute Effects of Medium Chain Triglyceride), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04584346 phase1completednot on this map

Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson s Disease (PD) Symptoms and Biomarkers (MCT-PD)

TypeinterventionalSponsorNational Institute of Neurological Disorders and Stroke (NINDS)Ran2021 to 2021Enrolled21ConditionsParkinson's DiseaseArmsLiquigen MCT oil, Standard American Diet
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Alexander H ChoiNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. choi.alexander7@gmail.com.
Melanie DelgadoNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Kong Y ChenNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Stephanie T ChungNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Amber CourvilleNIH Clinical Center Nutrition Department, National Institutes of Health, Bethesda, MD, USA.
Sara A TurnerNIH Clinical Center Nutrition Department, National Institutes of Health, Bethesda, MD, USA.
Shanna YangNIH Clinical Center Nutrition Department, National Institutes of Health, Bethesda, MD, USA.
Kayla AiraghiNIH Clinical Center Nutrition Department, National Institutes of Health, Bethesda, MD, USA.
Irene DustinNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Patrick McGurrinNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Tianxia WuNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Mark HallettNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Debra J EhrlichNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
National Institutes of Health · USNational Institutes of Health Clinical Center · USNational Institute of Neurological Disorders and Stroke · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA ketogenic diet (KD) may benefit people with neurodegenerative disorders marked by mitochondrial depolarization/insufficiency, including Parkinson's disease (PD).

objectiveEvaluate whether a KD supplemented by medium chain triglyceride (MCT-KD) oil is feasible and acceptable for PD patients. Furthermore, we explored the effects of MCT-KD on blood ketone levels, metabolic parameters, levodopa absorption, mobility, nonmotor symptoms, simple motor and cognitive tests, autonomic function, and resting-state electroencephalography (rsEEG).

methodsA one-week in-hospital, double-blind, randomized, placebo-controlled diet (MCT-KD vs. standard diet (SD)), followed by an at-home two-week open-label extension. The primary outcome was KD feasibility and acceptability. The secondary outcome was the change in Timed Up & Go (TUG) on day 7 of the diet intervention. Additional exploratory outcomes included the N-Back task, Unified Parkinson's Disease Rating Scale, Non-Motor Symptom Scale, and rsEEG connectivity.

resultsA total of 15/16 subjects completed the study. The mean acceptability was 2.3/3, indicating willingness to continue the KD. Day 7 TUG time was not significantly different between the SD and KD groups. The nonmotor symptom severity score was reduced at the week 3 visit and to a greater extent in the KD group. UPDRS, 3-back, and rsEEG measures were not significantly different between groups. Blood ketosis was attained by day 4 in the KD group and to a greater extent at week 3 than in the SD group. The plasma levodopa metabolites DOPAC and dopamine both showed nonsignificant increasing trends over 3 days in the KD vs. SD groups.

conclusionsAn MCT-supplemented KD is feasible and acceptable to PD patients but requires further study to understand its effects on symptoms and disease.

trial registrationTrial Registration Number NCT04584346, registration dates were Oct 14, 2020 - Sept 13, 2022.

Indexed as

Diet, KetogenicParkinson DiseaseDouble-Blind MethodFeasibility StudiesHumansLevodopaTriglyceridesLevodopaTriglyceridesBiomarkerClinical trialKetogenic dietKetosisParkinson’s diseasePilot study

Identifiers

PMID38561682
PMCPMC10983636
OpenAlexW4393389004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.